Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
|
|
- Jasper Lamb
- 6 years ago
- Views:
Transcription
1 Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
2 OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN HAVIN A LAUGH - ABAN
3 Profile of the ideal anticoagulant Minimal interactions with drugs or food Reversible Wide therapeutic window Oral administration and fixed dosing Reduced bleeding risk Rapid onset and offset of activity No laboratory monitoring Predictable dose response Furie & Furie. N Engl J Med 2008;359: ; Turpie. Eur Heart J 2007;29:
4
5 NICE technology appraisal guidance on NOACs in VTE Apixaban Recommended as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults 1 Recommended as an option for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery 2 Rivaroxaban Recommended as an option for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism after a diagnosis of acute deep vein thrombosis in adults 3 Recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults 4 Recommended as an option for the prevention of venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery 5 Dabigatran Recommended as an option for the primary prevention of venous thromboembolic events in adults who have undergone elective total hip replacement surgery or elective total knee replacement surgery 6 Recommended as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults 7 Edoxaban Recommended as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults 8
6 Clinical pharmacology of NOACs Mechanism of action Oral bioavailability Apixaban 1,2 Rivaroxaban 1,3 Dabigatran 1,4 Edoxaban 5 Direct factor Xa inhibitor Direct factor Xa inhibitor Direct thrombin inhibitor Direct factor Xa inhibitor ~50% % ~6.5% ~62% Pro-drug No No Yes No Food effect No Yes (20 mg and 15 mg doses need to be taken with food) Renal clearance ~27% ~33 %* 85% 50% Mean half-life (t 1/2 ) 12 h 5 9 h (young) h (elderly) No h (patients) No h T max 3 4 h 2 4 h h 1 2 h
7 Rivaroxaban is increasingly used to treat patients with acute venous thromboembolism (VTE), a potentially life-threatening condition. Because absorption of rivaroxaban decreases from nearly 100% to 66% under fasting conditions, it is recommended that VTE patients take rivaroxaban with a meal. We describe a case of a compliant young patient who developed recurrent pulmonary embolism during rivaroxaban treatment. PK studies provided evidence that malabsorption of rivaroxaban 20 mg due to irregular intake of meals was the leading cause of recurrent pulmonary embolism. When the patient was instructed to take rivaroxaban with a regular meal, peak plasma concentrations increased from 115 to 318 ng ml 1 (+ 176%). Consequently, the importance of taking rivaroxaban with food may have a greater clinical relevance than data from preclinical PK studies suggest.
8
9 Warfarin only NVAF, acute and long term prevention DVT/ PE Warfarin experienced CrCl <15 Weight >120kg Acute venous thrombosis not involving the legs/ lung Drug interactions (CYP3A4 and P-gp inhibitors)
10 Aims Atrial fibrillation choice Acute VTE choice Prevention of recurrent VTE choice
11 Atrial fibrillation
12 DOACs: Stroke, systemic embolism vs warfarin SSE vs warfarin (ITT population) %/yr Warfarin %/yr HR (95% CI) Dabigatran 150 mg ¹ ( ) Dabigatran 110 mg ² ( ) Rivaroxaban ³ ( ) Apixaban ( ) SSE = stroke and systemic embolism Favours new orals Favours warfarin No head to head studies have been conducted between any of the NOACs. Therefore, no conclusions about the relative efficacy or safety of any of these drugs should be drawn from these data 1.Connolly SJ et al. N Engl J Med 2009;361: ; 2.Connolly SJ et al. N Engl J Med 2010;363: ; 3.Patel MR et al. NEJM 2011;365: and Supplementary Appendix; 4.Granger et al. N Eng J Med 2011;365:
13 DOACs: Intracranial bleeding vs warfarin Intracranial bleeding vs warfarin %/yr Warfarin %/yr HR (95% CI) Dabigatran 150 mg ¹ ( ) Dabigatran 110 mg ² ( ) Rivaroxaban ³ ( ) Apixaban ( ) Favours new orals Favours warfarin No head to head studies have been conducted between any of the NOACs. Therefore, no conclusions about the relative efficacy or safety of any of these drugs should be drawn from these data 1.Connolly SJ et al. N Engl J Med 2009;361: ; 2.Connolly SJ et al. N Engl J Med 2010;363: ; 3.Patel MR et al. NEJM 2011;365: and Supplementary Appendix; 4.Granger et al. N Eng J Med 2011;365:
14 Definition of major bleeding Fatal bleeding, and/or Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or Bleeding causing a fall in hemoglobin level of 20 g L 1 or more, or leading to transfusion of two or more units of whole blood or red cells.
15 DOACs: Major bleeding vs warfarin Major bleeding vs warfarin %/yr Warfarin %/yr HR (95% CI) Dabigatran 150 mg ¹ ( ) Dabigatran 110 mg ² ( ) Rivaroxaban ³ ( Apixaban ( ) Favours new orals Favours warfarin No head to head studies have been conducted between any of the NOACs. Therefore, no conclusions about the relative efficacy or safety of any of these drugs should be drawn from these data 1.Connolly SJ et al. N Engl J Med 2009;361: ; 2.Connolly SJ et al. N Engl J Med 2010;363: ; 3.Patel MR et al. NEJM 2011;365: and Supplementary Appendix; 4.Granger et al. N Eng J Med 2011;365:
16 DOACs: Any bleeding vs warfarin Any bleeding vs warfarin %/yr Warfarin %/yr HR (95% CI) Dabigatran 150 mg ¹ ( ) Dabigatran 110 mg ² ( ) Rivaroxaban ³ ( ) Apixaban ( ) * major and non-major clinically relevant bleeding (excludes minimal bleeding) Favours new orals Favours warfarin 1.5 No head to head studies have been conducted between any of the NOACs. Therefore, no conclusions about the relative efficacy or safety of any of these drugs should be drawn from these data 1.Connolly SJ et al. N Engl J Med 2009;361: ; 2.Connolly SJ et al. N Engl J Med 2010;363: ; 3.Patel MR et al. NEJM 2011;365: and Supplementary Appendix; 4.Granger et al. N Eng J Med 2011;365:
17 Cumulative hazard AVERROES: Primary safety outcome -there was no statistically significant difference in the risk of MAJOR bleeding between apixaban and ASA Apixaban 5mg BD (in 94% of patients) Apixaban ASA Months HR 1.13 (95% CI: ); p=0.57 No. at Risk Apixaban ASA Patients with 2 of the following received a reduced dose of 2.5 mg bd [6.4% of patients]: age 80 years, weight 60 kg, serum creatinine 1.5 mg/dl (133 μmol/l) Note: Per the SmPC, patients with the exclusive criterion of severe renal impairment (CrCl15 29 ml/min) should also receive the lower dose of apixaban 2.5 mg twice daily. This new criterion differs from the trial conduct. Adapted from Connolly et al. N Engl J Med 2011;364:
18 Which DOAC to use in AF? Savelieva et al, Clin Cardiol 2014
19 Acute VTE NOAC trial exclusion criteria
20 NOAC trial designs in acute VTE treatment NOAC Trial Number of patients Design Parenteral required before NOAC? NOAC dosing Comparator Treatment length (months) Follow-up period Key inclusion criteria Apixab an AMPLIFY 1 5,395 DVT: 3,532 PE: 1,836 Double-blind No Apixab an 10 mg twiceda ily for 7d, then 5 mg twice daily Enoxaparin bridge to warfarin 6 30 days after study completion DVT/PE requiring treatment for 6 months Dabiga tran RE-COVER 2 2,539 DVT:1,749 PE: 786 RE-COVER II 3 2,568 DVT: 1,750 PE: 816 Double-blind Required for at least 5 days Dabigat ran 150 mg twice daily Enoxaparin bridge to warfarin 6 30 days after study completion DVT of the legs/pe requiring treatment for 6 months Rivaro xaban EINSTEIN-DVT 4 DVT: 3,449 Open-label No Rivarox aban 15 mg twice daily for 21d, then 20 mg once daily Enoxaparin bridge to VKA 3, 6, or 12* For duration of treatment DVT without PE EINSTEIN-PE 5 PE: 4,832 PE with or without DVT Edoxaba n Hokusai-VTE 6 8,240 DVT: 4,921 PE: 3,319 Double-blind Enoxaparin or UFH 5 days Edoxaban 60 mg once daily Enoxaparin bridge to warfarin 3 12 For duration of treatment DVT without PE PE with or without DVT There are no head-to-head studies between these agents. There are limitations such as differing patient populations, designs and outcomes, and caution should therefore be exercised when interpreting these findings. No conclusions about the relative efficacy or safety of any of these agents should be drawn from these data. Please refer to individual product SmPCs for further information
21 AMPLIFY: primary efficacy outcome and key safety outcomes The AMPLIFY trial was a double-blind, randomised trial comparing 6 months of apixaban treatment with enoxaparin bridging to warfarin therapy in patients with acute symptomatic DVT and/or PE Primary efficacy outcome* Recurrent VTE or VTErelated death, n (%) Safety outcomes# Apixaban (n=2,609) Enoxaparin/ warfarin (n=2,635) 59 (2.3) 71 (2.7) Apixaban (n=2,676) Enoxaparin/ warfarin (n=2,689) RR (95% CI) 0.84 ( ) RR (95% CI) P Value <0.001 Noninferiority P Value Major bleeding, n (%) 15 (0.6) 49 (1.8) 0.31 ( ) <0.001 Major or CRNM bleeding, n (%) 115 (4.3) 261 (9.7) 0.44 ( ) < Favours apixaban 1 Favours 2 enoxaparin/warfarin Agnelli et al. N Engl J Med. 2013;369:
22 RE-COVER: primary efficacy outcome and key safety outcomes The RE-COVER trial was a double-blind, double-dummy, randomised trial comparing 6 months of dabigatran treatment (150 mg twice daily) with heparin* bridging to dose-adjusted warfarin therapy in patients with acute symptomatic DVT and/or PE Dabigatran (n=1,274) Heparin*/ warfarin (n=1,265) HR (95% CI) P Value Primary efficacy outcome# Recurrent VTE or VTErelated death, n (%) 30 (2.4) 27 (2.1) 1.10 ( ) <0.001 Non-inferiority Dabigatran (n=1,273) Heparin*/ warfarin (n=1,266) HR (95% CI) P Value Safety outcomes Major bleeding, n (%) 20 (1.6) 24 (1.9) 0.82 ( ) Data not available from publication Major or CRNM bleeding, n (%) 71 (5.6) 111 (8.8) 0.63 ( ) Favours dabigatran Favours warfarin Schulman et al. N Engl J Med. 2009;361:
23 EINSTEIN-PE: primary efficacy outcome and key safety outcomes The EINSTEIN-PE trial was an open-label, randomised trial comparing rivaroxaban treatment (15 mg twice daily for 21d, then 20 mg once daily for 3, 6 or 12 months) with enoxaparin bridging to VKA therapy in patients with acute symptomatic PE with or without symptomatic DVT Rivaroxaban (n=2,419) Enoxaparin/ VKA (n=2,413) Primary efficacy outcome* (mean study duration: ~9 months) HR (95% CI) P Value Recurrent VTE, n (%) 50 (2.1) 44 (1.8) 1.12 ( ) Non-inferiority Rivaroxaban (n=2,412) Enoxaparin/ VKA (n=2,405) HR (95% CI) P Value Safety outcomes# Major or CRNM bleeding, n (%) 249 (10.3) 274 (11.4) 0.90 ( ) 0.23 Major bleeding, n (%) 26 (1.1) 52 (2.2) 0.49 ( ) Favours rivaroxaban 1 Favours 2 enoxaparin/vka The EINSTEIN-PE Investigators. N Engl J Med. 2012;366:
24 HOKUSAI-VTE: primary efficacy outcome and key safety outcomes The HOKUSAI-VTE trial was a randomised, double-blind, non-inferiority trial comparing edoxaban treatment (60 mg once daily for 3 to 12 months)* with warfarin in patients with acute symptomatic DVT or symptomatic PE with or without DVT Edoxaban (n=4,118) Warfarin (n=4,122) HR (95% CI) P Value Primary efficacy outcome# (efficacy evaluated at 12 months regardless of treatment duration) Recurrent VTE or VTE-related death, n (%) 130 (3.2) 146 (3.5) 0.89 ( ) <0.001 Non-inferiority Edoxaban (n=4,118) Warfarin (n=4,122) HR (95% CI) P Value Safety outcomes First major or CRNM bleeding, n (%) 349 (8.5) 423 (10.3) 0.81 ( ) Major bleeding, n (%) 56 (1.4) 66 (1.6) 0.84 ( ) Favours edoxaban 1 Favours warfarin 2 Büller et al. N Engl J Med. 2013;369:
25
26 Higher recurrence rates in unprovoked VTE Cumulative incidence of recurrent VTE (%) % 20.5% Provoked VTE Unprovoked VTE Years after first VTE p<0.001 Data from patients with non-active cancer Adapted from Martinez et al. Thromb Haem 2014; 112. epub ahead of print. Martinez et al. Thromb Haem 2014;112. epub ahead of print.
27 ACCP guidance 2012 In patients with an unprovoked PE, we recommend treatment with anticoagulation for at least 3 months over treatment of a shorter duration In patients with a first VTE that is unprovoked proximal and who have a low or moderate bleeding risk we suggest extended anticoagulant therapy over 3 months of therapy. In patients with a first VTE that is unprovoked and who have a high bleeding risk, we recommend 3 months of anticoagulant therapy over extended therapy.
28 Age >65 Age >75 Previous bleeding Cancer Metastatic cancer Renal failure Liver failure Thrombocytopenia Diabetes Anaemia Antiplatelet therapy Poor anticoagulant control Comorbidity and reduced functional capacity Recent surgery Frequent falls Alcohol abuse Previous stroke Estimated absolute risk of major bleeding Categorisation of risk of Low(Zero risk factors) Moderate (1 risk factor) High (>2 risk factors) bleeding Anticoagulation 0-3 months Baseline risk(%) Increased risk (%) Total risk (%) Anticoagulation beyond 3 months Baseline risk (%/year) >2.5 Increased risk (%/year) >4.0 Total risk (%/year) >6.5
29 NOAC trial designs for prevention of recurrent VTE Study drug Trial Number of patients Treatment before randomisation Study drug dosing Comparator Treatment length (months) Apixaban AMPLIFY-EXT 1 2, months of standard therapy or apixaban Apixaban 2.5 mg or 5 mg twice daily* Placebo 12 Dabigatran RE-SONATE 2 1, months of VKA or dabigatran Dabigatran 150 mg twice daily Placebo 6 Rivaroxaban EINSTEIN- EXT 3 1,196 6 or 12 months of VKA or rivaroxaban Rivaroxaban 20 mg once daily Placebo 6 or 12 Edoxaban HOKUSAI- VTE 4 8,240 No preceding anticoagulation Edoxaban 60 mg Warfarin 3 to 12 once daily # Dabigatran RE-MEDY 2 2, months of VKA or dabigatran Dabigatran 150 mg twice daily Warfarin INR There are no head-to-head studies between these agents. There are limitations such as differing patient populations, designs and outcomes, and caution should therefore be exercised when interpreting these findings. No conclusions about the relative efficacy or safety of any of these agents should be drawn from these data. Please refer to individual product SmPCs for further information 1. Agnelli et al. N Engl J Med. 2013;368: ; 2. Schulman et al. N Engl J Med. 2013;368: ; 3. The EINSTEIN Investigators. N Engl J Med. 2010;363: ; 4. Büller et al. N Engl J Med. 2013;369:
30
31 AMPLIFY-EXT: apixaban had a comparable rate of major bleeding compared to placebo Patients with event (%) 4.0 Major bleeding RR (95% CI) 0.49 ( ) p value not calculated Major or CRNM bleeding RR (95% CI) 1.20 ( ) p value not calculated /840 22/ /840 4/829 Apixaban2.5 Primary safety Placebo endpoint mg BD Major Apixaban or CRNM Placebo bleeding 2.5 mg BD Agnelli et al. N Engl J Med 2013; 368:
32 NOAC dosing regimens across each stage of VTE treatment Initial VTE treatment Ongoing VTE Treatment Prevention of Recurrent VTE Apixaban 1 10 mg BD Day mg BD Day 8 onwards for at least 3 months* 2.5 mg BD Following completion of 6 months of treatment with apixaban 5 mg BD or another oral anticoagulant Rivaroxaban 2 15 mg BD with food Day mg OD with food Day 22 onwards for at least 3 months* Dabigatran 3 Parenteral anticoagulant For at least 5 days (not to be taken concomitantly with dabigatran) 150 mg BD For at least 3 months* (Dose adjustments to 110 mg BD in patients 80 years, patients on concomitant verapamil, and those at high risk of bleeding) Edoxaban 4 Parenteral anticoagulant For at least 5 days (not to be taken concomitantly with edoxaban) 60 mg OD For at least 3 months* (Dose adjustment required to 30 mg OD in patients with CrCl ml/min or body weight 60 kg or with concomitant use of the following P-gp inhibitors: ciclosporin, dronedarone, erythromycin or ketoconazole. Refer to edoxaban SmPC for further information) 1. Apixaban SmPC. July 2014; 2. Rivaroxaban SmPC. August 2014; 3. Dabigatran SmPC. June 2014; 4. Edoxaban SmPC. July 2015.
33 Summary AF, prescribe for stroke prevention reduction and low bleeding risk. Acute VTE, low risk, DOAC appropriate, outpatient based If in patient, do not rush to start DOAC Acute VTE, high risk, haemodynamic compromise, SoC?long term prevention of recurrence beyond 3 months
34
The clinical relevance of AMPLIFY programme
Venice October 16th 2015 The clinical relevance of AMPLIFY programme Francesco Dentali Department of Clinical Medicine Insubria University Varese Disclosures Bayer Bristol-Myers Squibb/Pfizer Boehringer
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationEvidences for real-life use in fragile patients: Renal failure and cancer
Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationDiagnosis and Management of Venous Thromboembolism
Diagnosis and Management of Venous Thromboembolism Muhammad Sajid Pervaiz Consultant Haematologist Chairman VTE committee Pennine Acute Hospitals NHS trust TOPICS 1-Introduction (Seriousness of problem)
More informationA Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism
Cardiol Ther (2018) 7:1 13 https://doi.org/10.1007/s40119-018-0107-0 REVIEW A Review of the Role of Non-Vitamin K Oral Anticoagulants in the Acute and Long-Term Treatment of Venous Thromboembolism Andrew
More informationAn Overview of Non Vitamin-K Antagonist Oral Anticoagulants. Helen Williams Consultant Pharmacist for CV Disease South London
An Overview of Non Vitamin-K Antagonist Oral Anticoagulants Helen Williams Consultant Pharmacist for CV Disease South London Contents Drugs and drug classes Licensed indications and NICE recommendations
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationA Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations
A Review of Direct-Acting Oral Anticoagulants (DOACs) and Their Use in Special Populations Allison Bernard, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics October 25 th,
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationWhen and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD
When and How to Use the Newly Approved Oral Anticoagulants to Treat Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) Ian del Conde, MD December 12, 2015 Disclosures CONSULTANT Merck; New Haven
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationOral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study.
Oral rivaroxaban versus standard therapy for the acute and continued treatment of symptomatic deep vein thrombosis. The EINSTEIN DVT study Comments Harald Darius, Berlin Disclosures for Harald Darius Research
More informationTreatment Options and How They Work
Treatment Options and How They Work Robin Offord Director of Clinical Pharmacy UCL Hospitals NHS Foundation Trust robin.offord@uclh.nhs.uk Introducing the term anticoagulant... What they do Inhibit the
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationUpdates in venous thromboembolism. Cecilia Becattini University of Perugia
Updates in venous thromboembolism Cecilia Becattini University of Perugia News for VTE Diagnosis Treatment the acute phase the agents Pulmonary embolism: diagnosis Vein ultrasonography Meta-analysis 15
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationDuration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium
Duration of Anticoagulation? Peter Verhamme MD, PhD Department of Cardiovascular Medicine University of Leuven Belgium Disclosures Honoraria and research support: Daiichi-Sankyo, Boehringer Ingelheim,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationAcute and long-term treatment of PE. Cecilia Becattini University of Perugia
Acute and long-term treatment of PE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE What is the optimal acute phase treatment for the patient? Intravenous thrombolysis One
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationTerapia Anticoagulante Oggi: Il Valore Aggiunto Dei Noacs Versus La Terapia Standard; Gli Eventi Avversi In PS Noemi Renzi PS/OBI NOA (MS); ATNO.
Terapia Anticoagulante Oggi: Il Valore Aggiunto Dei Noacs Versus La Terapia Standard; Gli Eventi Avversi In PS Noemi Renzi PS/OBI NOA (MS); ATNO. Consiglio Regionale SIMEU Toscana Stato dell arte.. La
More informationDOACs in CAT. Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD
DOACs in CAT Fellow: Shweta Jain, MD Faculty Discussant: David Garcia, MD Case 65 year old post menopausal female Left breast lesion Oct 2015 Biopsy Invasive ductal carcinoma Lumpectomy with SNB- pt1cno
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationObesity, renal failure, HIT: which anticoagulant to use?
Obesity, renal failure, HIT: which anticoagulant to use? Mark Crowther with thanks to Dr David Garcia and others. This Photo by Unknown Author is licensed under CC BY-SA 1 2 Drug choices The DOACs have
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationNon commercial use only. The treatment of venous thromboembolism with new oral anticoagulants. Background
Italian Journal of Medicine 2013; volume 7(s8):29-35 The treatment of venous thromboembolism with new oral anticoagulants Davide Imberti AUSL Piacenza, Italy ABSTRACT Traditional anticoagulants, such as
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationUnderstanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism. Rajat Deo, MD, MTR
Understanding Best Practices in Anticoagulation Therapy in Patients with Venous Thromboembolism Rajat Deo, MD, MTR Director of Translational Research in Cardiac Arrhythmias Division of Cardiovascular Medicine
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationABSTRACT INTRODUCTION
Adv Ther (2014) 31:473 493 DOI 10.1007/s12325-014-0119-7 REVIEW Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationEdoxaban. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation NICE approved the reproduction of its content for this booklet. NICE is independent of any
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationBenefit risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism
Review Article 231 Benefitrisk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism Jan Beyer-Westendorf 1 ; Walter Ageno 2 1 Center for Vascular Diseases
More informationPRACTICAL GUIDE LIXIANA (edoxaban)
NICE RECOMMENDED AND SMC ACCEPTED IN NVAF AND VTE 1-4 PRACTICAL GUIDE LIXIANA (edoxaban) For clinical data and prescriber resources please visit www.lixiana.co.uk Please refer to the Prescribing Information
More informationNew Anticoagulants and Emerging Strategies
New Anticoagulants and Emerging Strategies in the Treatment of Venous Thromboembolism b Stavros V. Konstantinides, MD, PhD, FESC Head, Department of Cardiology, Democritus University of Thrace, Greece
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationThe spectrum of clinical outcome of PE
Practical treatment approach for patients with PE Cecilia Becattini University of Perugia The spectrum of clinical presentation of PE PE-related shock Mild clinical symptoms The spectrum of clinical outcome
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationKeynote lecture: Oral anticoagulation and DVT
Keynote lecture: Oral anticoagulation and DVT What is the evidence? Is there a need to anticoagulate every lower leg DVT? Disclosure Speaker name:...sebastian Schellong... I have the following potential
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationXarelto (rivaroxaban)
Xarelto (rivaroxaban) Policy Number: 5.01.575 Last Review: 7/2018 Origination: 6/2014 Next Review: 7/2019 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Xarelto
More informationUSE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY
SDSHP ANNUAL MEETING CLINICAL PEARLS APRIL 7 TH, 2017 USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY STEFFANIE DANLEY, PHARM D, BCPS, CACP DISCLOSURE I have had no financial relationship over the past 12
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationTechnology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta341
Apixaban for the treatment and secondary prevention ention of deep vein thrombosis and/or pulmonary embolism Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta341 NICE 2017. All
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationEdoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354)
Rationale for Initiation, Continuation and Discontinuation (RICaD) Edoxaban Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (NICE TA354) This document supports the
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral
More informationUHL Guideline for Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults, with Direct Oral Anti-Coagulants
UHL Guideline for Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults, with Direct Oral Anti-Coagulants Trust Ref B11/2018 1. Introduction and Who Guideline applies to The introduction
More informationDaiichi Sankyo s Once-Daily Lixiana
Daiichi Sankyo s Once-Daily Lixiana (edoxaban) Receives Positive CHMP Opinion for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention
More informationDRUG NAME: EDOXABAN (LIXIANA ) Transfer of Care document Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationMy Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)?
My Cancer Patient Has a Clot- Can I prescribe a Direct Oral Anticoagulant (DOAC)? November 24, 2018 Erica Peterson MD, FRCPC University of British Columbia Disclosures I participate in clinical research
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationCancer Associated Thrombosis: six months and beyond. Farzana Haque Hull York Medical School
Cancer Associated Thrombosis: six months and beyond Farzana Haque Hull York Medical School Disclosure I have no disclosure The Challenge of Anticoagulation in Patients with Venous Thromboembolism and Cancer
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationOverview of the Direct Oral Anticoagulants
Original Article Nedaa Skeik, MD Abhishek Sethi Michele Shepherd, PharmD From: Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN Address for correspondence: Nedaa Skeik, MD Minneapolis
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationVenous Thromboembolic Disease Update
Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada
More informationAcute and long-term treatment of VTE. Cecilia Becattini University of Perugia
Acute and long-term treatment of VTE Cecilia Becattini University of Perugia Acute and long-term treatment of VTE The goals The acute PE phase After the acute phase Treatment for VTE Goals of acute treatment
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationSupplementary Online Content
Supplementary Online Content Caldeira D, Canastro M, Barra M, et al. Risk of substantial intraocular bleeding with novel oral anticoagulants: systematic review and meta-analysis. JAMA Ophthalmol. Published
More informationFibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali
Fibrillazione Atriale Non Valvolare: Come Orientare La Scelta Dei Nuovi Anticoagulanti Orali Gianluca Botto, MD, FAAC, FESC Divisione di Cardiologia Ospedale Sant Anna, Como The Promise of NOAs Antithrombotic
More informationCancer Associated Thrombosis An update.
Cancer Associated Thrombosis An update. Simon Noble Marie Curie Professor of Supportive and Palliative Medicine Marie Curie Palliative Care Research Centre Cardiff University The coagulation pathway LIQUID
More information1 Introduction. Walter Ageno 1. demonstrate a broadly favorable benefit risk profile across multiple clinical indications.
Drugs R D (2015) 15:295 306 DOI 10.1007/s40268-015-0105-9 REVIEW ARTICLE Rivaroxaban: An Evaluation of its Cardiovascular Benefit Risk Profile Across Indications Based on Numbers Needed to Treat or Harm,
More information